EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment

Mohamed Hassanein iD, Li Xi, Rathi D Ryan, Zhan Harold Ye, Nessy Tania, Yamato Sano iD, Joshua Varghese iD, Diogo Branquinho, Anna Sapone

Clinical and Translational Science · 2026-05 · 19 (5)

DOI: 10.1111/cts.70562 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 27.04.2026. Verfasst von Mohamed Hassanein und 8 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Biomarkers, Pfizer Inc., Pearl River, New York, USA. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Biomarkers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their utility in routine monitoring and clinical trials. Blood‐based biomarkers offer a complementary approach, providing minimally invasive, readily accessible measures that can be repeatedly sampled over time. Emerging blood‐derived signatures, including gene expression profiles and circulating molecular inflammation scores, capture systemic immune activity and have shown promise in predicting treatment response, disease flares, and pharmacodynamic (PD) effects of therapies. Recent advances utilizing multi‐omics technologies and machine learning methods have further improved the predictive performance of blood‐based biomarkers, particularly in the context of biologic therapies such as anti–tumor necrosis factor agents. Despite these advances and growing promises, challenges related to validation, standardization, and clinical integration persist. This review focused on recent advances in blood‐based biomarkers for IBD, with an emphasis on their use in predicting treatment response and assessing pharmacodynamic effects in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesBiomarkersHumansTreatment OutcomeMultiomicsPredictive Value of TestsProteomics

Stichwörter der Autor:innen

IBDPDbiomarkermultiomicsnoninvasiveproteomicsserumtranscriptomicstreatment response

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Translational and Clinical Biomarkers, Pfizer Inc., Pearl River, New York, USA.
  • Clinical Omics & Biomarker Statistics, Pfizer Inc., Cambridge, Massachusetts, USA.
  • Pharmacometrics and Systems Pharmacology Pfizer Inc., Cambridge, Massachusetts, USA.
  • Clinical Pharmacology & Bioanalytics, Pfizer R&D Japan G.K, Tokyo, Japan.
  • Global Medical Affairs, Pfizer Inc, New York, New York, USA.
  • I&I Research Unit, Pfizer Inc., Cambridge, Massachusetts, USA.

ORCID-Profile: Mohamed Hassanein, Yamato Sano, Joshua Varghese

Zitieren

APA

Hassanein, M., Xi, L., Ryan, R. D., Ye, Z. H., Tania, N., Sano, Y., Varghese, J., Branquinho, D., & Sapone, A. (2026). Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70562

Vancouver

Hassanein M, Xi L, Ryan RD, Ye ZH, Tania N, Sano Y, et al. Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70562

BibTeX
@article{Hassanein2026,
  author = {Hassanein, Mohamed and Xi, Li and Ryan, Rathi D and Ye, Zhan Harold and Tania, Nessy and Sano, Yamato and Varghese, Joshua and Branquinho, Diogo and Sapone, Anna},
  title = {Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {5},
  doi = {10.1111/cts.70562}
}
Kostenlos starten →